Navigation Links
Moffitt cancer center researchers find novel predictor for MDS progression risk
Date:9/12/2012

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

The study published in the August issue of The Journal of Immunology.

Awareness of the condition increased earlier this year when ABC's "Good Morning America" co-anchor Robin Roberts announced that she is battling MDS. Formerly known as pre-leukemia, MDS is a collection of blood disorders. One in three patients with MDS develops bone marrow failure and progresses to acute myelogenous leukemia within the first few years after diagnosis.

MDS involves the ineffective production of blood cells in bone marrow and often leaves patients anemic and in need of frequent blood transfusions.

The disease may develop as the result of chemotherapy or radiation for cancer treatment or can be related to bone marrow failure resulting from frequent transfusions and subsequent iron overload. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, a patient's organs can become overloaded with iron, leading to heart failure, liver injury, susceptibility to infection and other complications. Bone marrow transplantation may be necessary.

Seeking to understand more about the development of MDS, Moffitt researchers and their colleagues investigated aspects of the immune system, particularly the role of regulatory T cells, also known as Tregs. Tregs, said the researchers, are well-defined players in tumor immune invasion in solid tumors, but little is known about the role Tregs play in pre-malignant human diseases.

"We investigated a Treg subset called 'effector memory Tregs,' " said study senior author Pearlie K. Epling-Burnette, Pharm.D., Ph.D., senior member of Moffitt's Immunology Department. "We found that changes in the physical characteristics, or phenotypes, of Tregs in MDS suggest that they may be recently activated in a manner similar to effector memory T cells. By looking at a patient's effector memory Treg cells, we were able to identify patients at higher risk for MDS progression."

An increase in effector memory Tregs likely reflects active immune suppression and may represent the earliest biomarker indicating conversion to an immunosuppressive microenvironment, the researchers said.

The team concluded that the changes to effector memory Treg phenotype may also be a useful tool for identifying MDS patients who may respond to specific classes of drugs. This would make inclusion of a patient's Treg status into prognostic and treatment models potentially valuable for informing therapy decisions for patients with MDS.

"Our study sheds light on a unique aspect of T cells and immunity in a pre-malignant model of disease and specifically implicates the importance of changes to effector memory Tregs," concluded Epling-Burnette and her co-authors. "Our findings specifically implicate effector Treg expansion in disease progression in MDS."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
2. Moffitt Cancer Center researchers study childhood melanoma characteristics
3. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
4. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
5. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
6. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
7. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
8. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
9. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
10. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
11. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology: